Teva Pharmaceutical Industries Limited (TEVA) P/E Ratio History
Fairly ValuedTrading at 32.5x, near 5Y avg of 36.5x · 75th percentile · In line with own history · Data 2001–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, Teva Pharmaceutical Industries Limited (TEVA) trades at a price-to-earnings ratio of 32.5x, with a stock price of $39.01 and trailing twelve-month earnings per share of $0.60.
The current P/E is 11% below its 5-year average of 36.5x. Over the past five years, TEVA's P/E has ranged from a low of 14.8x to a high of 133.7x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, TEVA trades at a 37% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.
Relative to the broader market, TEVA commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TEVA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TEVA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TEVA P/E vs Peers
Large-scale generic drug manufacturers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 87.9 | - | +158% | |
| $7B | 29.3 | - | -22% | |
| $1B | 28.7 | 3.84Best | +1883%Best | |
| $105B | 22.9 | - | +49% | |
| $52B | 30.6 | - | +325% | |
| $110B | 61.8 | - | -62% | |
| $161B | 20.7Lowest | - | -4% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TEVA Historical P/E Data (2001–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $33.88 | $0.60 | 56.5x | -31% |
| FY2026 Q1 | - | $30.12 | $1.33 | 22.6x | -72% |
| FY2025 Q4 | Dec 31 2025 | $31.21 | $1.20 | 26.0x | -68% |
| FY2025 Q3 | - | $20.20 | $0.60 | 33.7x | -59% |
| FY2021 Q4 | Dec 31 2021 | $8.01 | $0.38 | 21.1x | -74% |
| FY2021 Q3 | - | $9.74 | $0.66 | 14.8x | -82% |
| FY2017 Q1 | Mar 31 2017 | $32.09 | $0.24 | 133.7x | +63% |
| FY2016 Q4 | Dec 31 2016 | $36.25 | $0.29 | 125.0x | +53% |
| FY2016 Q3 | Sep 30 2016 | $46.01 | $1.80 | 25.6x | -69% |
| FY2016 Q2 | - | $50.23 | $1.57 | 32.0x | -61% |
| FY2016 Q1 | - | $53.51 | $1.92 | 27.9x | -66% |
| FY2015 Q4 | - | $65.64 | $1.82 | 36.1x | -56% |
| FY2015 Q3 | Sep 30 2015 | $56.46 | $2.07 | 27.3x | -67% |
| FY2015 Q2 | - | $59.10 | $2.97 | 19.9x | -76% |
| FY2015 Q1 | - | $62.30 | $3.21 | 19.4x | -76% |
| FY2014 Q4 | Dec 31 2014 | $57.51 | $3.56 | 16.2x | -80% |
| FY2014 Q3 | - | $53.75 | $3.21 | 16.7x | -80% |
| FY2014 Q2 | Jun 30 2014 | $52.42 | $3.03 | 17.3x | -79% |
| FY2014 Q1 | Mar 31 2014 | $52.84 | $1.63 | 32.4x | -60% |
| FY2013 Q4 | - | $40.08 | $1.50 | 26.7x | -67% |
| FY2013 Q3 | Sep 30 2013 | $37.78 | $1.42 | 26.6x | -68% |
| FY2013 Q2 | Jun 30 2013 | $39.20 | $0.49 | 80.1x | -2% |
| FY2013 Q1 | Mar 31 2013 | $39.68 | $2.01 | 19.8x | -76% |
| FY2012 Q4 | Dec 31 2012 | $37.34 | $2.24 | 16.7x | -80% |
| FY2012 Q3 | Sep 30 2012 | $41.41 | $2.44 | 17.0x | -79% |
| FY2012 Q2 | Jun 30 2012 | $39.44 | $3.56 | 11.1x | -86% |
| FY2012 Q1 | Mar 31 2012 | $45.06 | $3.21 | 14.0x | -83% |
| FY2011 Q4 | Dec 31 2011 | $40.36 | $3.08 | 13.1x | -84% |
| FY2011 Q3 | Sep 30 2011 | $37.22 | $2.63 | 14.2x | -83% |
| FY2011 Q2 | - | $48.22 | $2.75 | 17.5x | -79% |
| FY2011 Q1 | - | $50.17 | $2.99 | 16.8x | -80% |
| FY2010 Q4 | Dec 31 2010 | $52.13 | $2.94 | 17.7x | -78% |
| FY2010 Q3 | - | $52.75 | $3.23 | 16.3x | -80% |
| FY2010 Q2 | Jun 30 2010 | $51.99 | $2.80 | 18.6x | -77% |
| FY2010 Q1 | Mar 31 2010 | $63.08 | $2.50 | 25.2x | -69% |
| FY2009 Q4 | - | $56.18 | $2.22 | 25.3x | -69% |
| FY2009 Q3 | Sep 30 2009 | $50.56 | $1.04 | 48.6x | -41% |
| FY2009 Q2 | - | $49.34 | $1.09 | 45.3x | -45% |
| FY2009 Q1 | - | $45.05 | $1.16 | 38.8x | -53% |
| FY2008 Q4 | Dec 31 2008 | $42.57 | $0.83 | 51.3x | -37% |
| FY2008 Q3 | - | $45.79 | $2.30 | 19.9x | -76% |
| FY2008 Q2 | Jun 30 2008 | $45.80 | $2.17 | 21.1x | -74% |
| FY2008 Q1 | Mar 31 2008 | $46.19 | $2.15 | 21.5x | -74% |
| FY2007 Q4 | Dec 31 2007 | $46.48 | $2.42 | 19.2x | -77% |
| FY2007 Q3 | Sep 30 2007 | $44.47 | $2.28 | 19.5x | -76% |
| FY2007 Q2 | Jun 30 2007 | $41.25 | $2.38 | 17.3x | -79% |
| FY2007 Q1 | Mar 31 2007 | $37.43 | $2.34 | 16.0x | -80% |
| FY2006 Q4 | Dec 31 2006 | $31.08 | $0.49 | 63.4x | -23% |
| FY2006 Q3 | Sep 30 2006 | $34.09 | $0.35 | 97.4x | +19% |
| FY2006 Q2 | Jun 30 2006 | $31.59 | $0.01 | 3159.0x | +3757% |
| FY2005 Q4 | Dec 31 2005 | $43.01 | $1.56 | 27.6x | -66% |
| FY2005 Q3 | Sep 30 2005 | $33.42 | $1.55 | 21.6x | -74% |
| FY2005 Q2 | - | $31.14 | $1.53 | 20.4x | -75% |
| FY2005 Q1 | - | $30.99 | $1.52 | 20.4x | -75% |
| FY2004 Q4 | Dec 31 2004 | $29.86 | $0.42 | 71.1x | -13% |
| FY2004 Q3 | - | $25.95 | $0.32 | 81.1x | -1% |
| FY2004 Q2 | Jun 30 2004 | $33.59 | $0.21 | 160.0x | +95% |
| FY2004 Q1 | Mar 31 2004 | $31.68 | $0.24 | 132.0x | +61% |
| FY2003 Q4 | Dec 31 2003 | $28.36 | $1.21 | 23.4x | -71% |
| FY2003 Q3 | - | $28.60 | $1.14 | 25.1x | -69% |
| FY2003 Q2 | Jun 30 2003 | $28.45 | $1.05 | 27.1x | -67% |
| FY2003 Q1 | Mar 31 2003 | $20.82 | $0.84 | 24.8x | -70% |
| FY2002 Q4 | - | $19.30 | $0.75 | 25.7x | -69% |
| FY2002 Q3 | Sep 30 2002 | $16.75 | $0.65 | 25.8x | -69% |
| FY2002 Q2 | May 31 2002 | $16.76 | $0.61 | 27.5x | -66% |
| FY2002 Q1 | Mar 31 2002 | $13.67 | $0.56 | 24.4x | -70% |
| FY2001 Q4 | Dec 31 2001 | $15.41 | $0.50 | 30.8x | -62% |
Average P/E for displayed period: 81.9x
TEVA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TEVA — Frequently Asked Questions
Quick answers to the most common questions about buying TEVA stock.
What is TEVA's P/E ratio?
Teva Pharmaceutical Industries Limited (TEVA) trailing twelve-month P/E ratio is 32.5x, based on TTM diluted EPS of $0.60. The 5-year average P/E is 36.5x and the historical range spans 14.8x to 133.7x.
Is TEVA stock overvalued or undervalued?
TEVA trades at 32.5x P/E, near its 5-year average of 36.5x. The 75th percentile ranking within the 14.8x–133.7x historical range places valuation within normal bounds.
Is TEVA stock expensive?
TEVA is fairly valued relative to its own history. The current P/E of 32.5x is near the 5-year average of 36.5x (75th percentile of historical range).
What is TEVA's historical P/E range?
Over the past 5 years, TEVA's P/E ratio has ranged from 14.8x to 133.7x, with a median of 26.7x and an average of 36.5x. The current P/E of 32.5x places the stock at the 75th percentile of this range. Full historical data spans 2001–2026.
How does TEVA's P/E compare to the S&P 500?
TEVA trades at 32.5x P/E versus the S&P 500 median of 25.3x. The 28% premium to the market typically reflects higher expected earnings growth or quality.
How does TEVA's valuation compare to Healthcare peers?
Teva Pharmaceutical Industries Limited P/E of 32.5x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TEVA's PEG ratio?
TEVA PEG ratio is N/A, based on a P/E of 32.5x and EPS growth of 182.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TEVA's earnings yield?
TEVA earnings yield is 3.08%, the inverse of its 32.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.